GRTP1

Chr 13

growth hormone regulated TBC protein 1

Also known as: TBC1D6

GRTP1 encodes a protein that acts as a GTPase-activating protein for Rab family proteins, regulating vesicle trafficking in the cytoplasm and at the plasma membrane. The gene shows very low constraint against loss-of-function variants (pLI near 0, LOEUF 1.63), suggesting it tolerates protein-truncating mutations well. No established human disease associations have been reported for GRTP1 mutations.

Summary from RefSeq, UniProt
Research Assistant →
0
Active trials
0
Pubs (1 yr)
117
P/LP submissions
0%
P/LP missense
1.63
LOEUF
Multiple*
Mechanism· predicted
Clinical SummaryGRTP1
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
117 unique Pathogenic / Likely Pathogenic· 76 VUS of 230 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
1.63LOEUF
pLI 0.000
Z-score -0.41
OE 1.11 (0.771.63)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint
-0.44Z-score
OE missense 1.09 (0.971.21)
230 obs / 211.8 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios
LoF OE1.11 (0.771.63)
00.351.4
Missense OE1.09 (0.971.21)
00.61.4
Synonymous OE1.16
01.21.6
LoF obs/exp: 18 / 16.2Missense obs/exp: 230 / 211.8Syn Z: -1.17
DN
0.7132th %ile
GOF
0.7126th %ile
LOF
0.2678th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

230 submitted variants in ClinVar

Classification Summary

Pathogenic114
Likely Pathogenic3
VUS76
Likely Benign21
Benign1
114
Pathogenic
3
Likely Pathogenic
76
VUS
21
Likely Benign
1
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
114
0
114
Likely Pathogenic
0
0
3
0
3
VUS
0
66
10
0
76
Likely Benign
0
4
17
0
21
Benign
0
0
1
0
1
Total0701450215

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

GRTP1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →